6 citations · 13 across the 5 of their papers we have counts for
Showing 2018Show all
2 papers · 1 filter
stat.ME2018★ 2 cited
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
Ruitao Lin, Robert L Coleman, Ying Yuan
Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of…
stat.ME2018★ 4 cited
Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials
Ruitao Lin, Ying Yuan
Two useful strategies to speed up drug development are to increase the patient accrual rate and use novel adaptive designs. Unfortunately, these two strategies often conflict when…